2025
18-OR: Lower Incretin Effect and Reduced GIP Characterize the Metabolic Phenotype of People with Multiple Islet Autoantibodies and Normal Glucose Tolerance
GALDERISI A, MARCHIORI H, ALGUARD M, DESOUSA M, TICHY E, FLYNN A, GAGLIA J, DALLA MAN C, SHERR J. 18-OR: Lower Incretin Effect and Reduced GIP Characterize the Metabolic Phenotype of People with Multiple Islet Autoantibodies and Normal Glucose Tolerance. Diabetes 2025, 74 DOI: 10.2337/db25-18-or.Peer-Reviewed Original ResearchOral glucose tolerance testNormal glucose toleranceInsulin secretion rateGlucose tolerance testIncretin effectStage 0GLP-1Islet autoantibodiesTolerance testGlucose tolerancePreclinical type 1 diabetesStage 1Reduced incretin effectHormone GLP-1Iv glucose tolerance testType 1 diabetesMultiple islet autoantibodiesPhenotype of peopleOral minimal modelC-peptideMetabolic phenotypeGlucose profilesIncretinMeasurement of glucoseInsulin secretionWS16.05Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis. Data from the MODUL-CF study
Bonnel A, Galderisi A, Weiss L, Sermet-Gaudelus I, Besancon A, Letierce A, Sahki D, Group M. WS16.05Impact of elexacaftor/tezacaftor/ivacaftor on glucose tolerance in adolescents with cystic fibrosis. Data from the MODUL-CF study. Journal Of Cystic Fibrosis 2025, 24: s33. DOI: 10.1016/j.jcf.2025.03.586.Peer-Reviewed Original ResearchOral glucose tolerance testAbnormal glucose toleranceNormal glucose toleranceCF-related diabetesBaseline oral glucose tolerance testAbnormal glucose tolerance groupCystic fibrosisGlucose toleranceNormal glucose tolerance groupEffective CFTR modulatorsOGTT glucoseBMI z-scoreYear of treatmentImpaired fasting glucoseImpaired glucose toleranceGlucose tolerance testForced expiratory volumeCFTR modulatorsPulmonary infectionDecrease recurrenceBaseline characteristicsRelated diabetesFasting glucoseTolerance testInsulin treatmentThe Disposition Index in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes
Ismail H, Cuthbertson D, Galderisi A, Libman I, Jacobsen L, Moran A, Petrelli A, Atkinson M, Redondo M, Hannon T, Mather K, Sosenko J. The Disposition Index in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes. Diabetes 2025, 74: 1196-1204. PMID: 40173211, PMCID: PMC12185960, DOI: 10.2337/db24-1000.Peer-Reviewed Original ResearchConceptsFirst-phase insulin responseArea under the curveArea under the curve ratioType 1 diabetesB cell functionAutoantibody-positive individualsDPT-1Glucose tolerance testMatsuda indexDisposition indexRegression modelsDiabetic rangeAnalyzed cross-sectionallyTolerance testDiabetes Prevention Trial-Type 1Oral glucose tolerance testProgression to type 1 diabetesStudy participantsCox regression modelsAntibody-positive relativesInsulin secretionPrediction of T1DRisk scoreIntravenous glucose tolerance testMeasure of B-cell functionATGL links insulin dysregulation to insulin resistance in adolescents with obesity and hepatosteatosis
Slusher A, Santoro N, Vash-Margita A, Galderisi A, Hu P, Tokoglu F, Li Z, Tarabra E, Strober J, Vatner D, Shulman G, Caprio S. ATGL links insulin dysregulation to insulin resistance in adolescents with obesity and hepatosteatosis. Journal Of Clinical Investigation 2025, 135: e184740. PMID: 40091831, PMCID: PMC11910223, DOI: 10.1172/jci184740.Peer-Reviewed Original ResearchConceptsHyperinsulinemic-euglycemic clampSubcutaneous adipose tissueInsulin resistanceAdipose triglyceride lipaseInsulin infusionOral glucose tolerance testAbdominal fat distributionGlucose tolerance testMeasuring abdominal fat distributionLower liver fatActivating adipose triglyceride lipaseMetabolic disease riskLiver fat contentEctopic lipid storageFUNDINGThis workAdipose tissue lipolysisInhibition of adipose tissue lipolysisSubcutaneous adipose tissue samplesFat distributionTolerance testInsulin exposureLiver fatInfusionGlycerol turnoverAdipose tissueMetabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function
Galderisi A, Bonet J, Ismail H, Moran A, Fiorina P, Bosi E, Petrelli A. Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function. The Journal Of Clinical Endocrinology & Metabolism 2025, dgaf086. PMID: 39992257, DOI: 10.1210/clinem/dgaf086.Peer-Reviewed Original ResearchOral glucose tolerance testMetabolic phenotypeOral minimal modelInsulin secretionResponse to disease-modifying treatmentsOdds of disease progressionPhenotype of individualsPrevention trialsPreclinical type 1 diabetesIndependent of stageMeasures of beta-cell functionStage 1Glucose tolerance testAssociated with reduced oddsBeta-cell functionMeasures of insulin secretionType 1 diabetesOGTT-derived measuresIncreased insulin clearanceT1D prevention trialsIslet autoimmunityDisease-modifying treatmentsTolerance testDisease progressionProgression predictorsEffect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis
Galderisi A, Weiss L, Besançon A, Stremler N, Reix P, Wizla N, Lustre A, Rames C, Tatopoulos A, Perisson C, Dalphin M, Troussier F, Houdouin V, Bessaci K, Cosson L, Gabsi A, Corvol H, Deneuville E, Storni V, Ramel S, Bui S, Heraud M, Remus N, Huet F, Scalbert M, Mely L, Gachelin E, Giannantonio M, Letierce A, Sahki D, Marguet C, Bonnel A, Sermet-Gaudelus I. Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis. The Journal Of Clinical Endocrinology & Metabolism 2025, dgaf099. PMID: 39977216, DOI: 10.1210/clinem/dgaf099.Peer-Reviewed Original ResearchOral glucose tolerance testBaseline oral glucose tolerance testAbnormal glucose toleranceNormal glucose toleranceAbnormal glucose tolerance groupCystic fibrosisGlucose toleranceNormal glucose tolerance groupEffective CFTR modulatorsCF-related diabetesInsulin secretionImpaired fasting glucoseGlucose tolerance testImpaired glucose toleranceForced expiratory volumeBMIz-scoreCFTR modulatorsBaseline characteristicsRelated diabetesFasting glucoseTolerance testTherapeutic strategiesInsulin treatmentExpiratory volumeGlucose levels
2024
Association of gestational and childhood circulating C-peptide concentrations in the hyperglycemia and adverse pregnancy outcomes follow-up study
Rajamoorthi A, Zheng H, Skowronski A, Zork N, Reddy U, Tung P, Kupsco A, Gallagher D, Salem R, Leibel R, LeDuc C, Thaker V. Association of gestational and childhood circulating C-peptide concentrations in the hyperglycemia and adverse pregnancy outcomes follow-up study. Diabetes Research And Clinical Practice 2024, 220: 111967. PMID: 39716665, PMCID: PMC11840794, DOI: 10.1016/j.diabres.2024.111967.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testC-peptide concentrationsC-peptideInsulin sensitivityCord bloodFollow-up studyInsulinogenic indexHOMA-IRCirculating C-peptide concentrationsCord blood C-peptideMaternal glucose concentrationsBlood C-peptideBMI z-scoreGlucose tolerance testPancreatic beta-cell developmentBeta-cell developmentGestational ageOGTT glucoseMaternal fastingAssociations of gestationalPubertal stageTolerance testInsulin resistanceZ-scoreMaternal covariatesDaily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity
Barbieri E, Bonet J, Fox D, Nelson R, Nelson M, Nelson L, Fernandez C, Van Name M, Samuels S, Caprio S, Sabati M, Galderisi A, Sherr J, Man C, Santoro N. Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. Obesity 2024, 33: 116-124. PMID: 39658509, PMCID: PMC11666407, DOI: 10.1002/oby.24175.Peer-Reviewed Original ResearchConceptsIntrahepatic fat contentDaily glucose variabilityLiver proton density fat fractionProton density fat fractionGlucose variabilityInsulin sensitivityOral glucose tolerance testFat fractionInsulin secretionAssociated with insulin resistanceFirst-phase insulin secretionAssociated with 2-h glucoseGlucose tolerance testGlucose standard deviationMagnetic resonance imagingOral minimal modelCoefficient of variationBasal insulin secretionPediatric obesityPostprandial glucoseTolerance testCell sensitivityInsulin resistanceObesityResonance imagingRevisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes.
Martino M, Galderisi A, Evans-Molina C, Dayan C. Revisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes. Diabetes 2024, 73: 1769-1779. PMID: 39106185, DOI: 10.2337/db24-0163.Peer-Reviewed Original ResearchB cell functionBeta cell lossType 1 diabetesLoss of B-cell functionCell lossOral glucose tolerance testPreclinical type 1 diabetesEarly stage diseaseBeta cell destructionTime of diagnosisDestruction of B cellsGlucose tolerance testMonths prior to clinical diagnosisAntibody positivityStage diseaseDisease activityAutoimmune destructionB cellsDisease accelerationInsulin therapyTolerance testInsulin secretionSubmaximal stimuliCell destructionGlucose controlModeling Glucose, Insulin, C-Peptide, and Lactate Interplay in Adolescents During an Oral Glucose Tolerance Test.
Bonet J, Barbieri E, Santoro N, Dalla Man C. Modeling Glucose, Insulin, C-Peptide, and Lactate Interplay in Adolescents During an Oral Glucose Tolerance Test. Journal Of Diabetes Science And Technology 2024, 19322968241266825. PMID: 39076151, PMCID: PMC11572107, DOI: 10.1177/19322968241266825.Peer-Reviewed Original ResearchOral glucose tolerance testArea under the curveGlucose tolerance testC-peptideTolerance testStandard oral glucose tolerance testPathological conditionsTime coursePopulation of adolescentsClinical dataLactate metabolism pathwaysLiver diseaseSteatotic liver diseaseModel glucoseMetabolic diseasesIntersubject variabilityObesityLactate metabolismAnaerobic glycolysisInsulinLactate kineticsDiseaseAdolescentsLactateMetabolic pathways1507-P: Mixed-Meal Tolerance Test (MMTT) C-Peptide and BETA-2 Score Predict Underlying ß-Cell Secretory Capacity following Islet Transplantation for Type 1 Diabetes (T1D)
FLATT A, MATUS A, GALLOP R, MARKMANN E, DALTON-BAKES C, PELECKIS A, LIU C, NAJI A, RICKELS M. 1507-P: Mixed-Meal Tolerance Test (MMTT) C-Peptide and BETA-2 Score Predict Underlying ß-Cell Secretory Capacity following Islet Transplantation for Type 1 Diabetes (T1D). Diabetes 2024, 73 DOI: 10.2337/db24-1507-p.Peer-Reviewed Original ResearchMixed-meal tolerance testB-cell secretory capacityGlucose-potentiated arginineC-peptideBeta 2Secretory capacityBETA-2 scoreRepeated-measures correlation analysisYears post-transplantB cell functionIslet transplantationModerate effect sizeAllogeneic islet transplantationC-peptide/glucose ratioType 1 diabetesIslet graft functionGraft functionPost-transplantGraft monitoringTolerance testC-peptide/glucoseTransplantationLongitudinal cohortEffect sizeSS cells899-P: Combinations of the Mitochondrial Protonophore TLC-6740 and/or the ACC2 Inhibitor TLC-3595 Provide Additive Glycemic Benefits to Semaglutide (SEMA) in db/db Mice
VIJAYAKUMAR A, SRODA N, MURAKAMI E, WENG S, MYERS R, SUBRAMANIAN M, SHULMAN G. 899-P: Combinations of the Mitochondrial Protonophore TLC-6740 and/or the ACC2 Inhibitor TLC-3595 Provide Additive Glycemic Benefits to Semaglutide (SEMA) in db/db Mice. Diabetes 2024, 73 DOI: 10.2337/db24-899-p.Peer-Reviewed Original ResearchOral glucose tolerance testGLP-1R agonistsDb/db miceIncremental AUCGlucose tolerance testMale db/db miceImproved glucose toleranceSemaglutide groupGlycemic parametersSemaglutideTolerance testFood intakeGlucose toleranceGLP-1RLiver-targeted mitochondrial uncouplerDb/dbMiceGlucose bolusVEHAgonistsEvaluation of combinationsHbA1cDiabetesMitochondrial uncouplingAssess effectsModelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease: A pilot study
Bonet J, Fox D, Nelson R, Nelson M, Nelson L, Fernandez C, Barbieri E, Man C, Santoro N. Modelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease: A pilot study. Diabetes Obesity And Metabolism 2024, 26: 3207-3212. PMID: 38742538, DOI: 10.1111/dom.15648.Peer-Reviewed Original ResearchOral glucose tolerance testLiver diseaseSteatotic liver diseaseAssess putative differencesArea under the curveProton density fat fractionBody mass indexGlucose tolerance testTime-to-peakMann-Whitney testObese adolescentsSpearman correlation coefficientMass indexTolerance testMann-WhitneyFat fractionWilcoxon testGlucose metabolismInvestigate glucoseLactate production rateEvaluate differencesLactate metabolismObesityPutative differencesLactate kineticsAltered extracellular matrix dynamics is associated with insulin resistance in adolescent children with obesity
Slusher A, Nouws J, Tokoglu F, Vash‐Margita A, Matthews M, Fitch M, Shankaran M, Hellerstein M, Caprio S. Altered extracellular matrix dynamics is associated with insulin resistance in adolescent children with obesity. Obesity 2024, 32: 593-602. PMID: 38410080, PMCID: PMC11034857, DOI: 10.1002/oby.23974.Peer-Reviewed Original ResearchConceptsSubcutaneous adipose tissueLiver fat contentInsulin resistanceInsulin sensitivityEctopic storage of lipidOral glucose tolerance testGluteal subcutaneous adipose tissueExtracellular matrix dynamicsMagnetic resonance imaging scansAdipose tissueBody fat distribution patternsFibrogenesis in vivoAdipocyte turnoverAssociated with insulin resistanceGlucose tolerance testFat distribution patternsWhole-body IRAdipose tissue insulin signalingTissue insulin signalingTolerance testGluteal fatImaging scansPathophysiological pathwaysAssociated with ratioObesityPeri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients
Abdel-Karim T, Hodges J, Herold K, Pruett T, Ramanathan K, Hering B, Dunn T, Kirchner V, Beilman G, Bellin M. Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients. Transplant International 2024, 37: 12320. PMID: 38357216, PMCID: PMC10864605, DOI: 10.3389/ti.2024.12320.Peer-Reviewed Original ResearchConceptsAlpha 1-antitrypsinTolerance testPerioperative periodAlpha-1 antitrypsin treatmentMixed meal tolerance testBenefit of etanerceptMeal tolerance testTrial of etanerceptGlucose tolerance testMonths post-TPIATIntravenous glucose tolerance testIslet autotransplant recipientsLong-term diabetes outcomesSerum A1ATEtanercept groupAdministered etanerceptAutotransplant recipientsDiabetes outcomesInflammatory profileEtanerceptIL-10Endogenous upregulationMCP-1Randomized trialsInflammatory cytokinesAbsence of adverse maternal and neonatal outcomes in patients with 1 or 2 abnormal values during early glucose tolerance testing
Geng B, Lundsberg L, Culhane J, Merriam A. Absence of adverse maternal and neonatal outcomes in patients with 1 or 2 abnormal values during early glucose tolerance testing. American Journal Of Obstetrics And Gynecology 2024, 230: e103-e107. PMID: 38242338, DOI: 10.1016/j.ajog.2024.01.007.Peer-Reviewed Original Research
2023
THU302 Protective Effects Of Lactation On Maternal Metabolism
Hens J, Ding Y, Brown S, Song H, Wysolmerski J, De Aguiar R. THU302 Protective Effects Of Lactation On Maternal Metabolism. Journal Of The Endocrine Society 2023, 7: bvad114.737. PMCID: PMC10554876, DOI: 10.1210/jendso/bvad114.737.Peer-Reviewed Original ResearchNL miceGlucose metabolismL miceBody compositionEuglycemic hyperinsulinemic clamp techniquePlasma free fatty acidsHistory of lactationMaternal glucose metabolismTissue triglyceride levelsGlucose tolerance testType 2 diabetesEuglycemic hyperinsulinemic clampGlucose infusion rateAge-matched cohortNumber of isletsAge-matched virginsLiver triglyceridesInsulin levelsTriglyceride levelsLiver weightTolerance testInsulin secretionMaternal metabolismFree fatty acidsInfusion rateEffects of short‐term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial
Tas E, Landes R, Diaz E, Bai S, Ou X, Buchmann R, Na X, Muzumdar R, Børsheim E, Dranoff J. Effects of short‐term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial. Obesity 2023, 31: 2740-2749. PMID: 37731271, PMCID: PMC11519784, DOI: 10.1002/oby.23887.Peer-Reviewed Original ResearchConceptsHigh-intensity interval trainingCardiorespiratory fitnessOral glucose tolerance testDual-energy X-ray absorptiometryAttenuation parameter (CAP) scoreIntrahepatic triglyceride contentSerum alanine aminotransferaseGlucose tolerance testSteatotic liver diseaseX-ray absorptiometryLiver magnetic resonanceCardiometabolic markersCardiometabolic healthExercise trainingHIIT protocolsLiver diseaseLiver fatExercise protocolTolerance testCRF testAlanine aminotransferaseInterval trainingMRI-PDFFTriglyceride contentObesityOGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals
Ylescupidez A, Speake C, Pietropaolo S, Wilson D, Steck A, Sherr J, Gaglia J, Bender C, Lord S, Greenbaum C. OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals. The Journal Of Clinical Endocrinology & Metabolism 2023, 109: 57-67. PMID: 37572381, PMCID: PMC10735531, DOI: 10.1210/clinem/dgad472.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringClinical trialsPositive individualsOral glucose tolerance testPrediction of T1DGlucose tolerance testType 1 diabetesCGM dataTrialNet PathwayMultiple autoantibodiesT1D diagnosisTolerance testAncillary studiesContinuous glucose monitoring dataMultivariable modelCGM metricsInsufficient evidenceAcademic centersGlucose monitoring dataHigh discriminative abilityT1D predictionGlucose monitoringCGM measuresCharacteristic curveOGTTSumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial
Golubic R, Ismail M, Josipovic M, Kennet J, Galderisi A, Evans M. Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial. Diabetes Obesity And Metabolism 2023, 25: 3059-3063. PMID: 37312648, DOI: 10.1111/dom.15176.Peer-Reviewed Original ResearchConceptsPlacebo-controlled cross-over trialIntravenous glucose tolerance testGlucose tolerance testCross-over trialGlucose effectivenessTolerance testInsulin sensitivityInsulin secretionHyperinsulinaemic euglycaemic clampControl blood glucoseGlucoregulatory roleOverweight adultsOverweight humansEuglycaemic clampInsulin levelsGlucose excursionsBlood glucoseReceptor agonistMouse modelGlucose homeostasisSumatriptanPlaceboSecretionTrialsHumans
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply